While most current clinical experience in lupus has centered on CD19-directed CAR-T cells, growing evidence supports the therapeutic relevance of targeting B-cell maturation antigen (BCMA), a receptor expressed on long-lived plasma cells responsible for sustained autoantibody production. The gene discussed is CD19; the disease is systemic lupus erythematosus.